Payment overview · 2025
General Payments
$2,189.18
113 reported records · 29 companies
Healthcare provider profile · identity verified
Silvia E Coleman, MD
Allopathic & Osteopathic Physicians|Internal Medicine · NEW CASTLE, PA · NPI 1003807546
Verified facts
What the public records show
CMS Open Payments records show Silvia E Coleman, MD received $2,189.18 in general payments during 2025 across 113 reported records.
PFIZER INC. accounted for 11.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 46 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Arexvy, Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic, Rexulti, Rybelsus, Trelegy Ellipta, Trintellix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 227 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 263 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 559 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 811 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 212 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 559 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 2902 records involving 986 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Abilify Maintena by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 156 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 27924 records involving 10497 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Abilify Maintena by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 811 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Paxlovid by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $243.85 | 11.1% | 14 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $187.68 | 8.6% | 8 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $179.99 | 8.2% | 12 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $172.44 | 7.9% | 7 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $166.70 | 7.6% | 7 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $156.23 | 7.1% | 8 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $111.47 | 5.1% | 7 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $105.57 | 4.8% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $96.16 | 4.4% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $72.81 | 3.3% | 4 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $69.23 | 3.2% | 4 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $69.07 | 3.2% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $66.90 | 3.1% | 3 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $64.19 | 2.9% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $63.05 | 2.9% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $45.11 | 2.1% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $41.25 | 1.9% | 3 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $38.30 | 1.8% | 2 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $34.40 | 1.6% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $28.72 | 1.3% | 2 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $25.51 | 1.2% | 1 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $24.42 | 1.1% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $21.74 | 1.0% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $20.09 | 0.9% | 1 | 2025 |
| AppliedVR Inc | Unresolved — no canonical attribution shown | $18.44 | 0.8% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.67 | 0.8% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $17.22 | 0.8% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.97 | 0.8% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $14.00 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,135.64 | 111 |
| Education | $53.54 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $250.73 | 11 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $166.70 | 7 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $155.27 | 10 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $143.95 | 7 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $142.50 | 9 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $128.17 | 8 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $122.41 | 8 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $121.44 | 6 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $121.44 | 6 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $108.58 | 3 | 2025 |
Source payment records
|
|||||
| LOKELMA Normalized: lokelma |
Drug | AstraZeneca Pharmaceuticals LP | $107.31 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $99.42 | 5 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $96.16 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $93.12 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $90.23 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $90.02 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $86.79 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $85.32 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $85.32 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $72.81 | 4 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $69.23 | 4 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $69.07 | 3 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $69.07 | 3 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $64.19 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $56.68 | 3 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $47.12 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $45.11 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $41.25 | 3 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $38.30 | 2 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $34.40 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $28.72 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $26.15 | 2 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $25.51 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $24.72 | 2 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $24.42 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $21.74 | 1 | 2025 |
Source payment records
|
|||||
| JASCAYD Normalized: jascayd |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $19.78 | 1 | 2025 |
Source payment records
|
|||||
| M-M-R II Normalized: m m r ii |
Biological | Merck Sharp & Dohme LLC | $18.45 | 1 | 2025 |
Source payment records
|
|||||
| RelieVRx Normalized: relievrx |
Device | AppliedVR Inc | $18.44 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $17.67 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $17.22 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $16.97 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.55 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.55 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $14.00 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $12.28 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 24 | exact normalized | Medicare Part D |
| AREXVY arexvy |
2025 | Arexvy | 2024 | 12 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 811 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 263 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 559 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 86 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 61 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 156 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 212 | exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 72 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
227 | 43 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
100 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
263 | 35 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
559 | 73 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
811 | 80 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
212 | 46 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
559 | 73 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
86 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
63 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 2902 supporting records · 986 recipient NPIs · example record 1251759994 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
61 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
156 | 22 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 27924 supporting records · 10497 recipient NPIs · example record 1227267721 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
24 | 24 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
811 | 80 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
39 | 39 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
72 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1956 | 290 |
| Pantoprazole Sodium | Pantoprazole Sodium | 1588 | 230 |
| Amlodipine Besylate | Amlodipine Besylate | 1555 | 281 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1380 | 233 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1051 | 231 |
| Gabapentin | Gabapentin | 1006 | 146 |
| Furosemide | Furosemide | 986 | 139 |
| Metoprolol Succinate | Metoprolol Succinate | 829 | 147 |
| Eliquis | Apixaban | 811 | 80 |
| Omeprazole | Omeprazole | 792 | 147 |
| Metformin Hcl | Metformin Hcl | 785 | 130 |
| Potassium Chloride | Potassium Chloride | 771 | 109 |
| Losartan Potassium | Losartan Potassium | 701 | 133 |
| Sertraline Hcl | Sertraline Hcl | 610 | 85 |
| Famotidine | Famotidine | 592 | 99 |
| Simvastatin | Simvastatin | 568 | 107 |
| Metoprolol Tartrate | Metoprolol Tartrate | 563 | 76 |
| Jardiance | Empagliflozin | 559 | 73 |
| Trazodone Hcl | Trazodone Hcl | 510 | 106 |
| Escitalopram Oxalate | Escitalopram Oxalate | 492 | 86 |
| Lisinopril | Lisinopril | 441 | 89 |
| Prednisone | Prednisone | 429 | 221 |
| Cefuroxime | Cefuroxime Axetil | 428 | 293 |
| Duloxetine Hcl | Duloxetine Hcl | 419 | 61 |
| Valsartan | Valsartan | 417 | 83 |
| Pravastatin Sodium | Pravastatin Sodium | 412 | 71 |
| Carvedilol | Carvedilol | 406 | 67 |
| Torsemide | Torsemide | 395 | 58 |
| Hydrochlorothiazide | Hydrochlorothiazide | 388 | 96 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 368 | 128 |
| Clopidogrel | Clopidogrel Bisulfate | 362 | 37 |
| Meloxicam | Meloxicam | 347 | 89 |
| Citalopram Hbr | Citalopram Hydrobromide | 342 | 45 |
| Buspirone Hcl | Buspirone Hcl | 340 | 60 |
| Donepezil Hcl | Donepezil Hcl | 331 | 31 |
| Allopurinol | Allopurinol | 329 | 54 |
| Tamsulosin Hcl | Tamsulosin Hcl | 316 | 47 |
| Xarelto | Rivaroxaban | 286 | 36 |
| Tramadol Hcl | Tramadol Hcl | 279 | 50 |
| Memantine Hcl | Memantine Hcl | 278 | 20 |
| Montelukast Sodium | Montelukast Sodium | 268 | 49 |
| Spironolactone | Spironolactone | 265 | 48 |
| Farxiga | Dapagliflozin Propanediol | 263 | 35 |
| Doxycycline Hyclate | Doxycycline Hyclate | 260 | 190 |
| Alprazolam | Alprazolam | 233 | 52 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 231 | 37 |
| Fluticasone Propionate | Fluticasone Propionate | 227 | 70 |
| Synthroid | Levothyroxine Sodium | 227 | 43 |
| Mirtazapine | Mirtazapine | 220 | 34 |
| Irbesartan | Irbesartan | 213 | 55 |
| Metformin Hcl Er | Metformin Hcl | 212 | 49 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 212 | 46 |
| Januvia | Sitagliptin Phosphate | 203 | 23 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 201 | 41 |
| Methylprednisolone | Methylprednisolone | 199 | 138 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 198 | 38 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 181 | 40 |
| Quetiapine Fumarate | Quetiapine Fumarate | 181 | 19 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 168 | 30 |
| Diclofenac Sodium | Diclofenac Sodium | 164 | 41 |
| Ondansetron Hcl | Ondansetron Hcl | 157 | 70 |
| Rybelsus | Semaglutide | 156 | 22 |
| Ibandronate Sodium | Ibandronate Sodium | 148 | 38 |
| Atenolol | Atenolol | 145 | 28 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 145 | suppressed |
| Lorazepam | Lorazepam | 145 | 42 |
| Glimepiride | Glimepiride | 143 | 32 |
| Azithromycin | Azithromycin | 141 | 114 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 132 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 130 | 16 |
| Alendronate Sodium | Alendronate Sodium | 128 | 38 |
| Fluoxetine Hcl | Fluoxetine Hcl | 127 | 14 |
| Benazepril Hcl | Benazepril Hcl | 123 | 25 |
| Divalproex Sodium | Divalproex Sodium | 123 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 122 | 31 |
| Bumetanide | Bumetanide | 122 | 19 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 120 | 28 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 118 | 35 |
| Warfarin Sodium | Warfarin Sodium | 118 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 116 | 88 |
| Tradjenta | Linagliptin | 116 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 114 | 19 |
| Glipizide | Glipizide | 109 | 18 |
| Ibuprofen | Ibuprofen | 107 | 32 |
| Celecoxib | Celecoxib | 106 | 23 |
| Myrbetriq | Mirabegron | 100 | 12 |
| Baclofen | Baclofen | 99 | 28 |
| Fluconazole | Fluconazole | 99 | 68 |
| Chlorthalidone | Chlorthalidone | 97 | 27 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 95 | 12 |
| Levofloxacin | Levofloxacin | 94 | 69 |
| Topiramate | Topiramate | 94 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 93 | 20 |
| Repaglinide | Repaglinide | 92 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 90 | 19 |
| Sucralfate | Sucralfate | 90 | 17 |
| Methocarbamol | Methocarbamol | 89 | 34 |
| Cephalexin | Cephalexin | 88 | 65 |
| Mounjaro | Tirzepatide | 86 | 18 |
| Finasteride | Finasteride | 85 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 85 | 22 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 84 | 14 |
| Levetiracetam | Levetiracetam | 83 | 12 |
| Pregabalin | Pregabalin | 82 | suppressed |
| Risperidone | Risperidone | 82 | suppressed |
| Bupropion Xl | Bupropion Hcl | 80 | 19 |
| Dicyclomine Hcl | Dicyclomine Hcl | 80 | 19 |
| Humalog Kwikpen U-100 | Insulin Lispro | 78 | 18 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 75 | 13 |
| Clonazepam | Clonazepam | 73 | 12 |
| Vascepa | Icosapent Ethyl | 73 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 72 | 28 |
| Trintellix | Vortioxetine Hydrobromide | 72 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 71 | suppressed |
| Amoxicillin | Amoxicillin | 70 | 38 |
| Hydralazine Hcl | Hydralazine Hcl | 70 | 12 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 67 | 19 |
| Ketoconazole | Ketoconazole | 66 | 45 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 65 | 40 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 64 | 15 |
| Trulicity | Dulaglutide | 63 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 63 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 62 | 51 |
| Ipratropium Bromide | Ipratropium Bromide | 62 | 22 |
| Ozempic | Semaglutide | 61 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 60 | 16 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 58 | 11 |
| Fenofibrate | Fenofibrate | 58 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 58 | 15 |
| Labetalol Hcl | Labetalol Hcl | 57 | suppressed |
| Nystatin | Nystatin | 56 | 34 |
| Ezetimibe | Ezetimibe | 54 | 14 |
| Meclizine Hcl | Meclizine Hcl | 52 | 23 |
| Naproxen | Naproxen | 51 | 15 |
| Midodrine Hcl | Midodrine Hcl | 50 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 49 | 14 |
| Lamotrigine | Lamotrigine | 49 | suppressed |
| Ondansetron Odt | Ondansetron | 49 | 24 |
| Ramipril | Ramipril | 48 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 48 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 47 | 13 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 46 | suppressed |
| Novolog Flexpen | Insulin Aspart | 46 | 18 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 45 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 44 | 12 |
| Rabeprazole Sodium | Rabeprazole Sodium | 44 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 43 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 42 | suppressed |
| Verapamil Sr | Verapamil Hcl | 42 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 41 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 41 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 41 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 40 | suppressed |
| Latanoprost | Latanoprost | 40 | suppressed |
| Levemir Flexpen | Insulin Detemir | 40 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 40 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 40 | 22 |
| Verapamil Er | Verapamil Hcl | 40 | suppressed |
| Aripiprazole | Aripiprazole | 39 | suppressed |
| Folic Acid | Folic Acid | 39 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 39 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 39 | 39 |
| Cefdinir | Cefdinir | 38 | 34 |
| Icosapent Ethyl | Icosapent Ethyl | 38 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 38 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 38 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 38 | 14 |
| Valacyclovir | Valacyclovir Hcl | 38 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 38 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 37 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 37 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 37 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 36 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 35 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 35 | 28 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 35 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 34 | suppressed |
| Hydroxyurea | Hydroxyurea | 34 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 34 | suppressed |
| Linzess | Linaclotide | 34 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 34 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 34 | suppressed |
| Humalog | Insulin Lispro | 33 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 33 | suppressed |
| Metronidazole | Metronidazole | 33 | 22 |
| Insulin Aspart Flexpen | Insulin Aspart | 31 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 30 | suppressed |
| Calcitriol | Calcitriol | 30 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 30 | suppressed |
| Glipizide Er | Glipizide | 29 | 11 |
| Mupirocin | Mupirocin | 29 | 24 |
| Namzaric | Memantine Hcl/Donepezil Hcl | 29 | suppressed |
| Premarin | Estrogens, Conjugated | 29 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 28 | suppressed |
| Praluent Pen | Alirocumab | 28 | suppressed |
| Rexulti | Brexpiprazole | 28 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 28 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 27 | 13 |
| Diltiazem 24hr Er | Diltiazem Hcl | 27 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 27 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 27 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 26 | suppressed |
| Klor-Con M20 | Potassium Chloride | 26 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Metolazone | Metolazone | 26 | suppressed |
| Repatha Sureclick | Evolocumab | 26 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 24 | 24 |
| Digoxin | Digoxin | 24 | suppressed |
| Nitroglycerin | Nitroglycerin | 24 | 20 |
| Methotrexate | Methotrexate Sodium | 23 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 20 |
| Tobramycin | Tobramycin | 23 | 20 |
| Hydrocortisone | Hydrocortisone | 22 | 14 |
| Metoprolol-Hydrochlorothiazide | Metoprolol/Hydrochlorothiazide | 22 | suppressed |
| Novolog | Insulin Aspart | 22 | suppressed |
| Repatha Syringe | Evolocumab | 22 | suppressed |
| Eszopiclone | Eszopiclone | 21 | suppressed |
| Felodipine Er | Felodipine | 21 | suppressed |
| Loperamide | Loperamide Hcl | 21 | 11 |
| Restasis | Cyclosporine | 21 | suppressed |
| Armour Thyroid | Thyroid,pork | 20 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 20 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 20 | suppressed |
| Fentanyl | Fentanyl | 20 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | 11 |
| Diltiazem Hcl | Diltiazem Hcl | 19 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 19 | 18 |
| Ibu | Ibuprofen | 19 | suppressed |
| Lacosamide | Lacosamide | 19 | suppressed |
| Lactulose | Lactulose | 19 | suppressed |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Primidone | Primidone | 19 | suppressed |
| Admelog Solostar | Insulin Lispro | 18 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 18 | 16 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 18 | suppressed |
| Cefadroxil | Cefadroxil | 18 | suppressed |
| Mirabegron Er | Mirabegron | 18 | suppressed |
| Olanzapine | Olanzapine | 18 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 17 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 17 | suppressed |
| Ultra-Fine Original Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 16 | suppressed |
| Budesonide Dr | Budesonide | 16 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | 11 |
| Mesalamine Dr | Mesalamine | 16 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 16 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Telmisartan | Telmisartan | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 15 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 15 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 14 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 14 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 14 | 14 |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Arformoterol Tartrate | Arformoterol Tartrate | 13 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 13 | suppressed |
| Glyburide | Glyburide | 13 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 13 | suppressed |
| Indapamide | Indapamide | 13 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Timolol Maleate | Timolol Maleate | 13 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 12 | 12 |
| Belbuca | Buprenorphine Hcl | 12 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Nyamyc | Nystatin | 12 | suppressed |
| Roflumilast | Roflumilast | 12 | suppressed |
| Ssd | Silver Sulfadiazine | 12 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 12 | suppressed |
| Ursodiol | Ursodiol | 12 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 12 | suppressed |
| Abilify Maintena | Aripiprazole | 11 | suppressed |
| Anagrelide Hcl | Anagrelide Hcl | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 11 | suppressed |
| Dropsafe Pen Needle | Pen Needle, Diabetic, Safety | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 11 | 11 |
| Lovastatin | Lovastatin | 11 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 11 | suppressed |
| Modafinil | Modafinil | 11 | suppressed |
| Nabumetone | Nabumetone | 11 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,189.18 · 113 records | PFIZER INC. | ABRYSVO, ACCRUFER, AFREZZA, AIRSUPRA, AREXVY, BREZTRI, CAPLYTA, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, GARDASIL 9, GVOKE HYPOPEN, JARDIANCE, JASCAYD, Kerendia, LOKELMA, M-M-R II, MOUNJARO, NEXLETOL, NURTEC ODT, NUZYRA, OFEV, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, REXULTI, RelieVRx, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, TRINTELLIX, UBRELVY, UNITHROID, VOQUEZNA, VRAYLAR, Veozah, Wegovy, XIFAXAN, YUPELRI, ZEPBOUND, ZORYVE | 24 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error